Endometrium

Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000; 76:287–90. Mutter GL, Baak JP, Crum CP, et al. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000; 190:462–9. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000; 13:295–308. Scully RE, Bonfiglio TA, Kurman RJ, et al. Histological typing of female genital tract tumours. World Health Organization International Histological Classification of Tumours, 2nd ed. Berlin: Springer-Verlag, 1994, pp. 13–28. Ferenczy A, Mutter G. Endometrial hyperplasia and neoplasia: Definition, diagnosis and management Principles. In: Sciarra J (ed) Gynecology and obstetrics looseleaf CD-ROM, Lippincott, Williams & Wilkins, 2000. Philadelphia. Mutter GL. Premalignant Lesions of the Endometrium. A project from the Endometrial Collaborative Group. Available at URL: http://www.endometrium.org/. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92:924–30. Kendall BS, Ronnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998; 22:1012–19. Bergeron C, Nogales FF, Masseroli M, et al. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol 1999; 23:1102–8. Silverberg SG. Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. Mod Pathol 2000; 13:309–27. Pettersson B, Adami HO, Lindgren A, et al. Endometrial polyps and hyperplasia as risk factors for endometrial carcinoma. A case-control study of curettage specimens. Acta Obstet Gynecol Scand 1985; 64:653–9. Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982; 6:93–108. Sherman ME, Bitterman P, Rosenshein NB, et al. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992; 16:600–10. Moll UM, Chalas E, Auguste M, et al. Uterine papillary serous carcinoma evolves via a p53-driven pathway. Hum Pathol 1996; 27:1295–300. Deligdisch L, Holinka CF. Endometrial carcinoma: two diseases? Cancer Detect Prev 1987; 10:237–46. Hoffman K, Nekhlyudov L, Deligdisch L. Endometrial carcinoma in elderly women. Gynecol Oncol 1995; 58:198–201. Sherman ME, Silverberg SG. Advances in endometrial pathology. Clin Lab Med 1995; 15:517–43. Sherman ME, Sturgeon S, Brinton LA, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 1997; 10:963–8. Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995; 26:1260–7. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995; 26:1268–74. Sherman ME, Sturgeon S, Brinton L, et al. Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. J Cell Biochem Suppl 1995; 23:160–4. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80:827–41. Ries LAG, Eisner MP, Kosary CL, et al. (eds) SEER Cancer Statistics Review, 1973–1997. Bethesda, MD: National Cancer Institute, 2000. National Cancer Institute of Canada. Canadian Cancer Statistics 2000. Toronto, Canada: National Cancer Institute of Canada, 2000. Dhom G. Epidemiology of hormone-depending tumors. In:Voigt KD, Knabbe C (eds) Endocrine dependent tumors. New York: Raven Press, 1991, pp. 26–35. Hill HA, Eley JW, Harlan LC, et al. Racial differences in endometrial cancer survival: the black/white cancer survival study. Obstet Gynecol 1996; 88:919–26. Platz CE, Benda JA. Female genital tract cancer. Cancer 1995; 75(1 Suppl):270–94. SEER Cancer Incidence Public-Use Database, 1973–1995. August, 1997, submission. US Department of Health and Human Services, April, 1998. Franco EL. Epidemiology of uterine cancers. In: Meisels A, Morin C (eds) Cytopathology of the uterus, 2nd Ed. Chicago: American Society of Clinical Pathologists, 1997 (pp. 301–24). Schottenfeld D. Epidemiology of endometrial neoplasia. J Cell Biochem 1995; 23(Suppl.):151–9. Barrett RJ 2nd, Harlan LC, Wesley MN, et al. Endometrial cancer: stage at diagnosis and associated factors in black and white patients. Am J Obstet Gynecol 1995; 173:414–22; discussion 422-3. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985; 56:403–12 Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989; 160:126–31. Feldman S, Cook EF, Harlow BL, et al. Predicting endometrial cancer among older women who present with abnormal vaginal bleeding. Gynecol Oncol 1995; 56:376–81. Ben-Yehuda OM, Kim YB, Leuchter RS. Does hysteroscopy improve upon the sensitivity of dilatation and curettage in the diagnosis of endometrial hyperplasia or carcinoma? Gynecol Oncol 1998; 68:4–7. Farquhar CM, Lethaby A, Sowter M, et al. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstet Gynecol 1999; 181:525–9. Gredmark T, Kvint S, Havel G, et al. Adipose tissue distribution in postmenopausal women with adenomatous hyperplasia of the endometrium. Gynecol Oncol 1999; 72:138–42. Anastasiadis PG, Skaphida PG, Koutlaki NG, et al. Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding. Eur J Gynaecol Oncol 2000; 21:131–4. Koss LG, Schreiber K, Oberlander SG, et al. Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gynecol 1984; 64:1–11. Koss LG. Detection of occult endometrial carcinoma. J Cell Biochem Suppl 1995; 23:165–73. Vuento MH, Pirhonen JP, Makinen JI, et al. Screening for endometrial cancer in asymptomatic postmenopausal women with conventional and colour Doppler sonography. Br J Obstet Gynaecol 1999; 106:14–20. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994; 170:1213–23. Archer DF, Furst K, Tipping D, et al. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999; 94:498–503. Kurman RJ, Felix JC, Archer DF, et al. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol 2000; 96:373–9. Bjarnason K, Cerin A, Lindgren R, et al. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Maturitas 1999; 32:161–70. Bergeron C, Fox H. Low incidence of endometrial hyperplasia with acceptable bleeding patterns in women taking sequential hormone replacement therapy with dydrogesterone. Gynecol Endocrinol 2000; 14:275–81. Baak JP, Wisse-Brekelmans EC, Fleege JC, et al. Assessment of the risk on endometrial cancer in hyperplasia, by means of morphological and morphometrical features. Pathol Res Pract 1992; 188:856–9. Hunter JE, Tritz DE, Howell MG, et al. The prognostic and therapeutic implications of cytologic atypia in patients with endometrial hyperplasia. Gynecol Oncol 1994; 55:66–71. Janicek MF, Rosenshein NB. Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia. Gynecol Oncol 1994; 52:373–8. Ho SP, Tan KT, Pang MW, et al. Endometrial hyperplasia and the risk of endometrial carcinoma. Singapore Med J 1997; 38:11–15. Lindahl B, Willen R. Endometrial hyperplasia following estrogen treatment without the addition of gestagen. A follow-up study after withdrawal of estrogens. Anticancer Res 1991; 11:2071–3. Parazzini F, La Vecchia C, Bocciolone L, et al. The epidemiology of endometrial cancer. Gynecol Oncol 1991; 41:1–16. Weber AM, Belinson JL, Piedmonte MR. Risk factors for endometrial hyperplasia and cancer among women with abnormal bleeding. Obstet Gynecol 1999; 93:594–8. Daly MB, Bookman MA, Lerman CE. Female reproductive tract: cervix, endometrium, ovary. In: Greenwald P, Kramer BS, Weed DL (eds) Cancer Prev Control. New York: Marcel Dekker, 1995, pp. 585–610. Brinton LA, Barrett RJ, Berman ML, et al. Cigarette smoking and the risk of endometrial cancer. Am J Epidemiol 1993; 137:281–91. Weir HK, Sloan M, Kreiger N. The relationship between cigarette smoking and the risk of endometrial neoplasms. Int J Epidemiol 1994; 23:261–6. Sturgeon SR, Sherman ME, Kurman RJ, et al. Analysis of histopathological features of endometrioid uterine carcinomas and epidemiologic risk factors. Cancer Epidemiol Biomarkers Prev 1998; 7:231–5. Grady D, Ernster VL. Endometrial cancer. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention. New York: Oxford University Press, 1996, pp. 1058–89. Kreiger N, Marrett LD, Clarke EA, et al. Risk factors for adenomatous endometrial hyperplasia: a case-control study. Am J Epidemiol 1986; 123:291–301. Weiderpass E, Baron JA, Adami HO, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999; 353:1824–8. Horwitz RI, Feinstein AR. Alternative analytic methods for case-control studies of estrogens and endometrial cancer. N Engl J Med 1978; 299:1089–94. Rothman KJ, Greenland S. Modern Epidemiology, 2nd ed. Philadelphia: Lipincott-Raven, 1998, pp. 139–40. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996; 275:370–5. Grimbizis G, Tsalikis T, Tzioufa V, et al. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study. Hum Reprod 1999; 14:479–84. Beral V. Exogenous sex hormones and cancer. In: Lilienfeld AM (ed) Reviews in cancer epidemiology. New York: Elsevier, 1980, pp. 126–30. Kendrick JS, Wingo P, Rubin GL, et al. Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987; 257:796–800. Burke TW, Tortolero-Luna G, Malpica A, et al. Endometrial hyperplasia and endometrial cancer. Obstet Gynecol Clin North Am 1996; 23:411–56. Fisher B, Costantino JP, Redmond CK. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86:527–37. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer. Cancer Res 1988; 48:246–53. Baanders-van Halewyn EA, Blankenstein MA, Thijssen JH, et al. A comparative study of risk factors for hyperplasia and cancer of the endometrium. Eur J Cancer Prev 1996; 5:105–12. La Vecchia C, Decarli A, Fasoli M, et al. Nutrition and diet in the etiology of endometrial cancer. Cancer 1986; 57:1248–53. Bakour SH, Khan KS, Gupta JK. The risk of premalignant and malignant pathology in endometrial polyps. Acta Obstet Gynecol Scand 2000; 79:317–20. Cherkis RC, Patten SF Jr, Dickinson JC, et al. Significance of atypical endometrial cells detected by cervical cytology. Obstet Gynecol 1987; 69:786–9. Kurman RJ, Solomon D. The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses: Definitions, criteria, and explanatory notes for terminology and specimen adequacy. New York: Springer, 1994. Gomez-Fernandez CR, Ganjei-Azar P, Behshid K, et al. Normal endometrial cells in Papanicolaou smears: prevalence in women with and without endometrial disease. Obstet Gynecol 2000; 96:874–8. Nguyen TN, Bourdeau JL, Ferenczy A, et al. Clinical significance of histiocytes in the detection of endometrial adenocarcinoma and hyperplasia. Diagn Cytopathol 1998; 19:89–93. Hakala T, Mecklin JP, Forss M, et al. Endometrial carcinoma in the cancer family syndrome. Cancer 1991; 68:1656–9. Yancey M, Magelssen D, Demaurez A, et al. Classification of endometrial cells on cervical cytology. Obstet Gynecol 1990; 76:1000–5. Ferenczy A. Methods for detecting endometrial carcinoma and its precursors. In: Buchsbaum HJ, Sciarra JJ (eds) Gynecology and obstetrics, Vol. 4. New York: Harper & Row, 1982, pp. 1–8. Tsuda H, Kawabata M, Yamamoto K, et al. Prospective study to compare endometrial cytology and transvaginal ultrasonography for identification of endometrial malignancies. Gynecol Oncol 1997; 65:383–6. Grimes DA. Diagnostic dilation and curettage: a reappraisal. Am J Obstet Gynecol 1982; 142:1–6. Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding—a Nordic multicenter study. Am J Obstet Gynecol 1995; 172:1488–94. Goldstein SR. Saline infusion sonohysterography. Clin Obstet Gynecol 1996; 39:248–58. Takahashi S, Murakami T, Narumi Y, et al. Preoperative staging of endometrial carcinoma: diagnostic effect of T2-weighted fast spin-echo MR imaging. Radiology 1998; 206:539–47. Pritchard KI. Screening for endometrial cancer: is it effective? Ann Intern Med 1989; 110:177–9. Screening for Endometrial Cancer (PDQ). Screening/Detection—Health Professionals. US National Cancer Institute. Updated: August, 2000. Available at URL: http://cancernet.nci.nih.gov/pdq/pdq_screening.shtml. Jordan VC, Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 1994; 30A:1714–21. Suh-Burgmann EJ, Goodman A. Surveillance for endometrial cancer in women receiving tamoxifen. Ann Intern Med 1999; 131:127–35. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994; 170:447–51. Barakat RR. Benign and hyperplastic endometrial changes associated with tamoxifen use. Oncology 1997; 11(2 Suppl 1):35–7. Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer 2000; 7:73–83. Agorastos T, Bontis J, Vakiani A, et al. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data. Gynecol Oncol 1997; 65:102–14. Spitz IM, Chwalisz K. Progesterone receptor modulators and progesterone antagonists in women’s health. Steroids 2000; 65:807–15. Editor information Editors and Affiliations Rights and permissions Copyright information © 2002 Springer-Verlag New York, Inc. About this chapter Cite this chapter Franco, E.L., Ferenczy, A. (2002). Endometrium. In: Franco, E.L., Rohan, T.E. (eds) Cancer Precursors. Springer, New York, NY. https://doi.org/10.1007/0-387-21605-7_18 Download citation DOI: https://doi.org/10.1007/0-387-21605-7_18 Publisher Name: Springer, New York, NY Print ISBN: 978-0-387-95188-1 Online ISBN: 978-0-387-21605-8 eBook Packages: Springer Book Archive

- Endometrial Cancer - Obstet Gynecol - Endometrial Carcinoma - Endometrial Hyperplasia - Abnormal Uterine Bleeding These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.